Abbott awarded FDA approval for the new Abbott Vysis ALK Break Apart FISH Probe test for lung cancer.
M2 EQUITYBITES-August 29, 2011-Abbott awarded FDA approval for the new Abbott Vysis ALK Break Apart FISH Probe test for lung cancer(C)2011 M2 COMMUNICATIONS http://www.m2.com
Health company Abbott (NYSE:ABT) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for a new molecular diagnostic test, called The new Abbott Vysis ALK Break Apart FISH Probe test, for lung cancer.
The company stated new Abbott Vysis ALK Break Apart FISH Probe test is designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) patients for its approved NSCLC therapy, XALKORI (crizotinib).
This diagnostic test offers clinicians a standardised, clinically validated method to identify patients more likely to benefit from the new therapy.
Following the receipt of the simultaneous FDA approvals, the company expects to change the clinical practice for the diagnosis and treatment of patients with NSCLC.
In conjunction, the company stated the Vysis ALK FISH test will be available to clinicians and pathologists through Abbott Molecular.
((Comments on this story may be sent to firstname.lastname@example.org)).END.PUB430>PDAugust 29, 2011>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Aug 29, 2011|
|Previous Article:||UQM announces collaboration with ReGen Nautic USA Inc to expand into marine propulsion industry.|
|Next Article:||Ferrellgas Partners LP reports Q4 cash distribution of USD0.50 per common unit.|